SGX Market Updates

SGX 5 Best-Performing Healthcare Services Stocks Return 15% in 2019 YTD


PUBLISHED ON |

07 May 2019

  • The listed healthcare sector in Singapore, as tracked by the benchmark iEdge SG All Healthcare Index, comprises companies that operate in the segments of pharmaceuticals and biotechnology, healthcare and patient services, as well as medical equipment and supplies.

  • In the 2019 YTD, the iEdge SG All Healthcare Index has registered a price gain of +3.0%, compared with gains of 8.9% for the MSCI AC Asia ex-Japan Health Care Index and 7.7% for the MSCI ACWI Asia Health Care Index.

  • Over the last 10 years, the market cap of Singapore’s healthcare sector – comprising primary and secondary listings – has expanded nearly 13-fold. In comparison, the market cap of healthcare stocks listed in the Asia-Pacific region – for both emerging and developed markets – has grown by approximately 4x.

  • In the 2019 YTD, the 5 best-performing healthcare services providers on SGX were: ISEC Healthcare (+26.5%), Cordlife Group (+15.6%), Singapore Medical Group (+12.5%), Singapore O&G (+11.4%), and Medinex Ltd (+7.4%). The five have averaged a YTD total return of +14.7%.




Singapore’s healthcare sector is typically viewed as a defensive segment, poised to enjoy multi-year growth prospects. Drivers of Asia’s increased healthcare spending levels include accelerated ageing rates, the rise of lifestyle diseases like diabetes and hypertension, as well as growing disposable incomes. 

Frost & Sullivan estimates that the Asia-Pacific healthcare industry expanded by 11% to US$517 billion in 2018 – representing one of the fastest growing regions worldwide – compared with an average 4.8% growth rate for the global healthcare sector. The positive expansion is fuelled by increasing adoption of technology, innovative healthcare access programs and delivery of care outside traditional hospital settings.



Market Cap Growth in Last Decade

As a result, over the last 10 years, the market capitalisation of Singapore’s healthcare sector – comprising primary and secondary listings – has increased nearly 13-fold. In comparison, the market cap of healthcare stocks listed in the region’s emerging markets has grown by 4.4x, while the market value of healthcare listings in Asia’s developed markets has expanded by 3.8x, over the same period. 


SGX Healthcare Stocks Market Cap Growth




Performances of Singapore vs Asia’s Healthcare Indexes

The listed healthcare sector in Singapore, as tracked by the benchmark iEdge SG All Healthcare Index, comprises companies that operate in the segments of pharmaceuticals and biotechnology, healthcare and patient services, as well as medical equipment and supplies.

In the 2019 year-to-date, the iEdge SG All Healthcare Index has registered a price gain of 3.0%, compared with gains of 10.6% for the benchmark Straits Times Index (STI), 8.9% for the MSCI AC Asia ex-Japan Health Care Index, and 7.7% for the MSCI ACWI Asia Health Care Index.


SGX Healthcare Index Performance




Healthcare Services Providers Pursue Geographic Expansion

There are 18 healthcare service providers listed on SGX that operate patient care services and facilities in Singapore and worldwide. These facilities include laboratories, hospitals, nursing homes and clinics that offer services and treatments ranging from family medicine, dentistry, endoscopy and aesthetics to gynaecology, oncology, paediatrics, orthopaedics, ophthalmology and even cord blood banking. These 18 healthcare services plays have a combined market capitalisation of more than S$40 billion.

Some of the healthcare services companies that have listed on SGX in the last two years include Medinex Ltd (December 2018), Asian Healthcare Specialists (April 2018), Clearbridge Health (December 2017), and Aoxin Q & M Dental (April 2017).

The majority of Singapore’s healthcare service providers have also pursued international expansion plans in recent years. Their operations and assets span multiple geographies outside Singapore, including markets in South and Southeast Asia, Northeast Asia, as well as Middle East and Europe.

In particular, IHH Healthcare has medical centre and/or hospital operations in China, Hong Kong, India, Brunei and Malaysia, while its Europe and Middle East presence includes Mauritius, United Arab Emirates, Turkey, Bulgaria, Macedonia and the Netherlands. Likewise, OUE Lippo Healthcare has exposure to hospitals in China, Myanmar and Indonesia, as well as nursing and assisted living facilities in Japan. As for home-grown Raffles Medical Group, it now has a presence in 14 cities across Asia – operating hospitals in Hong Kong, Chongqing, Tianjin, Beijing and Shanghai, as well as clinics in Vietnam and Cambodia.

Investors can easily participate in the structural Asian healthcare theme through SGX-listed healthcare stocks that are rapidly expanding into regional and global markets to meet growing patient needs.



Best-Performing Healthcare Services Plays in YTD

In the 2019 YTD, the five best-performing healthcare service providers were: ISEC Healthcare (+26.5%), Cordlife Group (+15.6%), Singapore Medical Group (+12.5%), Singapore O&G (+11.4%), and Medinex Ltd (+7.4%). The five have averaged a YTD total return of +14.7%, bringing their one-year, three-year and five-year total returns to -4.6%, +29.9% and +19.4% respectively.

The tables below detail the 18 healthcare service providers listed on SGX, sorted by YTD total return.

Name SGX
Code
Market
Cap
S$m
Total
Return
YTD
%
Total
Return
1 Yr
%
Total
Return
3 Yr
%
Total
Return
5 Yr
%
ISEC HEALTHCARE 40T 158 26.5 13.0 30.4 NA
CORDLIFE GROUP P8A 110 15.6 -38.1 -69.4 -57.4
SINGAPORE MEDICAL 5OT 213 12.5 -7.2 181.2 154.2
SINGAPORE O&G 1D8 186 11.4 9.3 7.5 NA
MEDINEX LTD OTX 38 7.4 NA NA NA
OUE LIPPO HEALTHCARE 5WA 298 3.1 -40.2 3.5 -74.9
CLEARBRIDGE HEALTH 1H3 84 3.0 -67.2 NA NA
THOMSON MEDICAL A50 19,567 1.3 -16.5 -47.2 -18.6
HEALTH MGMT INTL 588 452 0.6 -17.2 74.1 233.5
IHH HEALTHCARE Q0F 15,697 0.0 -11.8 -21.0 21.1
ASIAN HEALTHCARE 1J3 83 -0.4 -13.1 NA NA
HC SURGICAL SPECIALISTS 1B1 86 -2.6 -12.6 NA NA
RAFFLES MEDICAL BSL 1,906 -3.6 -6.7 -29.0 -6.0
Q&M DENTAL QC7 369 -6.0 -22.3 -26.9 32.3
HEALTHWAY MEDICAL 5NG 131 -9.4 -40.8 -12.1 -54.0
AOXIN Q & M DENTAL 1D4 78 -10.9 -10.0 NA NA
TALKMED GROUP 5G3 690 -12.5 -22.5 18.5 29.8
ASIAMEDIC LTD 505 6.6 -19.0 -69.1 -75.4 -82.1
Average   0.9 -20.7 1.9 9.9


Name SGX
Code
Market
Cap
S$m
Dividend
Ind Yield
%
P/E
(x)
ROE
%
ISEC HEALTHCARE 40T 158 5.1 18.8 12.7
CORDLIFE GROUP P8A 110 0.8 26.7 3.5
SINGAPORE MEDICAL 5OT 213 NA 16.5 10.8
SINGAPORE O&G 1D8 186 4.4 20.3 20.8
MEDINEX LTD OTX 38 2.9 38.3 8.3
OUE LIPPO HEALTHCARE 5WA 298 NA NA -6.2
CLEARBRIDGE HEALTH 1H3 84 NA NA -34.0
THOMSON MEDICAL A50 19,567 0.3^ 180.5 1.6
HEALTH MGMT INTL 588 452 1.2 23.9 25.2
IHH HEALTHCARE Q0F 15,697 0.5 85.6 2.3
ASIAN HEALTHCARE 1J3 83 1.6 27.7 NA
HC SURGICAL SPECIALISTS 1B1 86 3.4 11.1 43.5
RAFFLES MEDICAL BSL 1,906 2.4 27.6 8.8
Q&M DENTAL QC7 369 1.7 25.9 12.8
HEALTHWAY MEDICAL 5NG 131 NA NA -3.2
AOXIN Q & M DENTAL 1D4 78 2.0 NA -0.2
TALKMED GROUP 5G3 690 3.5 22.6 38.4
ASIAMEDIC LTD 505 6.6 NA NA -70.7
Average 1.7 29.2 4.1

Source: Bloomberg & StockFacts (data as of 2 May 2019)
^ unpaid







This article is provided by SGX My Gateway.



SGX My Gateway

SGX's investor education portal with market, product and investment information and events. Sign up now at sgx.com/mygateway to receive our investment updates and economic calendar.

This document is not intended for distribution to, or for use by or to be acted on by any person or entity located in any jurisdiction where such distribution, use or action would be contrary to applicable laws or regulations or would subject Singapore Exchange Limited (“SGX”) to any registration or licensing requirement. This document is not an offer or solicitation to buy or sell, nor financial advice or recommendation for any investment product. This document is for general circulation only. It does not address the specific investment objectives, financial situation or particular needs of any person. Advice should be sought from a financial adviser regarding the suitability of any investment product before investing or adopting any investment strategies. Use of and/or reliance on this document is entirely at the reader’s own risk. Further information on this investment product may be obtained from www.sgx.com. Investment products are subject to significant investment risks, including the possible loss of the principal amount invested. Past performance of investment products is not indicative of their future performance. Examples provided are for illustrative purposes only. While each of SGX and its affiliates (collectively, the SGX Group Companies) have taken reasonable care to ensure the accuracy and completeness of the information provided, each of the SGX Group Companies disclaims any and all guarantees, representations and warranties, expressed or implied, in relation to this document and shall not be responsible or liable (whether under contract, tort (including negligence) or otherwise) for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind, including without limitation loss of profit, loss of reputation and loss of opportunity) suffered or incurred by any person due to any omission, error, inaccuracy, incompleteness, or otherwise, any reliance on such information, or arising from and/or in connection with this document. The information in this document may have been obtained via third party sources and which have not been independently verified by any SGX Group Company. No SGX Group Company endorses or shall be liable for the content of information provided by third parties. The SGX Group Companies may deal in investment products in the usual course of their business, and may be on the opposite side of any trades. SGX is an exempt financial adviser under the Financial Advisers Act (Cap. 110) of Singapore. The information in this document is subject to change without notice. This document shall not be reproduced, republished, uploaded, linked, posted, transmitted, adapted, copied, translated, modified, edited or otherwise displayed or distributed in any manner without SGX’s prior written consent.












Stock / REIT Search

Advertisement

Advertisement